Cystic Fibrosis Trial, Recruiting NCT06797206 Sponsor: Royal Brompton & Harefield NHS Foundation Trust Condition: Cystic Fibrosis
Back to Cystic Fibrosis

Cystic Fibrosis Trial, Recruiting

NCT06797206
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

'Mama' sub-study (for people with CF who are pregnant or planning pregnancy):

  • A person who is willing and able to give written agreement to take part in the study
  • A person who is already a patient at the Royal Brompton Hospital CF Reproductive and Maternal Health Service
  • A person who is 16 years of age or older at the time of joining the study
  • A person who has a confirmed diagnosis of cystic fibrosis (CF)
  • A person who is either pregnant or planning to become pregnant at the time of joining the study
  • A person who is able to attend the required appointments and complete the required tests

'Mini' sub-study (for babies with a parent who has CF):

  • A baby whose parent or guardian is willing and able to give written agreement for the baby to take part
  • A baby who has at least one biological parent with a confirmed CF diagnosis, where that parent is a patient at the Royal Brompton Hospital Adult CF Service
  • A baby who is under 12 months old at the time of the first visit
  • A baby whose family is able to attend the required appointments and complete the required tests

'Midi' sub-study (for young children with a parent who has CF):

  • A child whose parent or guardian is willing and able to give written agreement for the child to take part
  • A child who has at least one biological parent with a confirmed CF diagnosis, where that parent is a patient at the Royal Brompton Hospital Adult CF Service
  • A child who is between three and six years old at the time of the visit
  • A child whose family is able to attend the required appointments and complete the required tests

Who may not be able to join:

'Mama' sub-study:

  • A person who has a significant health condition that the study doctor believes would prevent them from safely following the study requirements
  • A person who has previously had a lung transplant

'Mini' sub-study:

  • A baby whose parent or guardian is not able to give consent for the baby to take part
  • A baby whose mother has significant health conditions unrelated to CF that the study doctor believes could affect the baby's health outcomes

'Midi' sub-study:

  • A child whose parent or guardian is not able to give consent for the child to take part
  • A child who has a significant health condition that the study doctor believes is known to affect lung function or lung imaging results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Imogen Felton, Royal Brompton Hospital and NHLI Imperial College London

Phone: 020 7352 8121

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Royal Brompton & Harefield NHS Foundation Trust
Registry
ClinicalTrials.gov
Start date
12 June 2025
Est. completion
1 April 2028

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Change in FEV1; Incidence of CF-related pulmonary complications during pregnancy.; Incidence of premature delivery; Frequency of liver dysfunction in infants; Incidence of congential abnormalities; Frequency of CF diagnoses in infants despite negative newborn screen testing; Frequency of abnormal lung clearance index results in young children

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov